Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

  1. Carmona-Bayonas, A.
  2. Jiménez-Fonseca, P.
  3. Lamarca, Á.
  4. Barriuso, J.
  5. Castaño, Á.
  6. Benavent, M.
  7. Alonso, V.
  8. Riesco-Martínez, M.D.C.
  9. Alonso-Gordoa, T.
  10. Custodio, A.
  11. Sánchez Cánovas, M.
  12. Hernando Cubero, J.
  13. López, C.
  14. Lacasta, A.
  15. Fernández Montes, A.
  16. Marazuela, M.
  17. Crespo, G.
  18. Escudero, P.
  19. Diaz, J.Á.
  20. Feliciangeli, E.
  21. Gallego, J.
  22. Llanos, M.
  23. Segura, Á.
  24. Vilardell, F.
  25. Percovich, J.C.
  26. Grande, E.
  27. Capdevila, J.
  28. Valle, J.W.
  29. García-Carbonero, R.
  30. Montrer des auteurs +
Revue:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology

ISSN: 1527-7755

Année de publication: 2019

Volumen: 37

Número: 28

Pages: 2571-2580

Type: Article

DOI: 10.1200/JCO.19.00980 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus